Trimethylamine N-oxide (TMAO) is a small organic compound that has garnered significant attention in recent years due to its association with cardiovascular health and disease. TMAO is derived from the oxidation of trimethylamine (TMA), which is produced by gut microbiota during the digestion of certain dietary nutrients, particularly choline, lecithin, and L-carnitine. These nutrients are predominantly found in red meat, eggs, dairy products, and some fish. Once TMA is absorbed into the bloodstream, it travels to the liver, where it is converted into TMAO by the enzyme flavin-containing monooxygenase 3 (FMO3).
The presence of TMAO in the bloodstream has been linked to various adverse health outcomes, most notably cardiovascular diseases (CVD). Elevated TMAO levels are associated with an increased risk of atherosclerosis, which is the buildup of fatty deposits in the arteries. This process can lead to the hardening and narrowing of arteries, impeding blood flow, and potentially resulting in heart attacks, strokes, and other cardiovascular events. One of the mechanisms by which TMAO promotes atherosclerosis is by enhancing the deposition of cholesterol in the arterial walls and impairing reverse cholesterol transport, a critical process in which cholesterol is removed from tissues and transported to the liver for excretion.
Beyond its impact on cholesterol metabolism, TMAO also influences platelet function, increasing the risk of thrombosis. This pro-thrombotic effect of TMAO can contribute to the formation of blood clots, which are dangerous as they can obstruct blood vessels and lead to acute cardiovascular events. Given these effects, TMAO is not only a marker of dietary intake and gut microbiota activity but also a potential therapeutic target for reducing cardiovascular risk.
The regulation of TMAO levels involves a multifaceted approach, including dietary modifications, gut microbiota modulation, and potentially pharmacological interventions. Reducing the intake of foods high in TMA precursors is a primary strategy. Additionally, promoting a healthy gut microbiota through probiotics and prebiotics can help mitigate the production of TMA. Research is also exploring the role of specific enzymes involved in TMA to TMAO conversion, which could lead to new treatments aimed at lowering TMAO levels.
Despite the established links between TMAO and cardiovascular health, the field is still evolving, with ongoing research aimed at better understanding the exact mechanisms and potential interventions. The complexity of TMAO's role in human health underscores the importance of a comprehensive approach that considers dietary habits, gut microbiota, genetic factors, and overall metabolic health. As science advances, the insights gained about TMAO will continue to shape strategies for preventing and managing cardiovascular diseases, highlighting the intricate connections between diet, gut health, and systemic disease processes.
TMAO
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →
All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.